Lausanne, Switzerland – December 7, 2012 -- Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, announces that Dr. Reddy’s Laboratories Ltd. launched Pamorelin® LA in India for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer on December 3.
Under the terms of the agreement, Dr. Reddy’s acquires exclusive marketing and sales rights for Pamorelin® LA Depot in India. The product is exported in bulk from Debio Recherche Pharmaceutique (Debio R.P.) to Dr. Reddy’s. Pamorelin® LA will be made available primarily to urologists and oncologists across India.
‘We recognise the need for prostate cancer treatment in India and are thrilled to have the opportunity to bring Pamorelin® LA to Indian patients’, said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. ‘This major step enables us to implement our strategy in one of the most important markets in Asia. This is only the logical continuation to a harmonious working relationship shared with Dr. Reddy’s over the years.’ Dr. Reddy’s and Debiopharm share the same vision to bring high-quality and safe ethical products to the highest number of patients suffering from serious diseases in India.
About Pamorelin® LA (active ingredient: triptorelin)
Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). In 1982, Debiopharm signed a licensing agreement for triptorelin with Tulane University in the US. Debiopharm has then developed three slow-release formulations (1, 3 and 6 months) of triptorelin pamoate. The 1- and 3-month-formulations have been registered in most countries and are currently available under the names of Trelstar® in North America, Decapeptyl® /Pamorelin® in Europe and Latin America and from now on, of Pamorelin® in India. The 6-month-formulation has been registered and is available in Europe and the US.
About Debiopharm Group™
Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.
For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.
About Debio R.P.
Debio Recherche Pharmaceutique (Debio R.P.), based in Martigny (Switzerland), is a pharmaceutical research, development and production company that has been Swissmedic and ANVISA (Brazil) certified, as well as inspected and registered by the American Food and Drug Administration (FDA) and the KFDA (South Korea). Debio R.P. is active in the discovery, formulation and development of peptides. Debio R.P. forms part of Debiopharm Group™ and employs 130 people, half of whom are university graduates or engineers.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) (Dr. Reddy’s) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand.
For more information, log on to: http://www.drreddys.com
Martina Schwarzkopf, Ph.D.
Account Supervisor
Russo Partners, LLC
12 West 27th Street, 4th Floor
New York, NY 10001
T (212) 845-4292
M (347) 591 8785
F (212) 845-4260
martina.schwarzkopf@russopartnersllc.com
www.russopartnersllc.com
